Dr. Brad H. Rovin, who is Co-Chair of the work group that design the KDIGO 2021 Clinical Practice Guidelines for the management of glomerular diseases, explains the present standards for managementn of lupus nephritis, and points towards future treatment options.
The interview was recorded on March 7th, 2022. Moderators: Prof. Dr. Kirsten de Groot (Offenbach, Germany), Priv.-Doz. Dr. Andreas Kronbichler (Cambridge, UK / Innsbruck, Austria) and Prof. Dr. Gunnar Heine (Frankfurt / Homburg, Germany).
Articles discussed:
Prediction models of treatment response in lupus nephritis.
Ayoub I, Wolf BJ, Geng L, Song H, Khatiwada A, Tsao BP, Oates JC, Rovin BH.
Kidney Int. 2022
doi: 10.1016/j.kint.2021.11.014
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group.
N Engl J Med. 2021 doi: 10.1056/NEJMoa2023386
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D et al.
N Engl J Med. 2021 doi: 10.1056/NEJMc2107725
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Jayne D, Rovin B et al.
Ann Rheum Dis. 2022
doi: 10.1136/annrheumdis-2021-221478
Expert Perspective: An Approach to Refractory Lupus Nephritis.
Arora S, Rovin BH. Arthritis Rheumatol. 2022 doi: 10.1002/art.42092
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Furie RA et al.
Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2021-220920
The lupus nephritis management renaissance.
Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH.
Kidney Int. 2022 doi: 10.1016/j.kint.2021.09.012
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.
Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P.
Clin J Am Soc Nephrol. 2018 doi: 10.2215/CJN.01070118
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Condon, M. B. et al.
Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202844
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH et al; LUNAR Investigator Group.
Arthritis Rheum. 2012 doi: 10.1002/art.34359
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH et al.
Lancet. 2021 doi: 10.1016/S0140-6736(21)00578-X
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group.
Kidney Int. 2021 doi: 10.1016/j.kint.2021.05.021.
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
Canadian Hydroxychloroquine Study Group.
N Engl J Med. 1991 doi: 10.1056/NEJM199101173240303.
Nephro JC. The Top Nephrology Stories of 2021
www.nephjc.com/news/2021/1/8/t...
KDIGO Glomerular Diseases Guideline Update Review: Part 2
• KDIGO Glomerular Disea...
NOBILITY Study
www.clinicaltrials.gov/ct2/sh...